Avantor (AVTR)
(Delayed Data from NYSE)
$25.31 USD
+0.18 (0.72%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $25.30 -0.01 (-0.04%) 7:58 PM ET
4-Sell of 5 4
C Value D Growth B Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$25.31 USD
+0.18 (0.72%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $25.30 -0.01 (-0.04%) 7:58 PM ET
4-Sell of 5 4
C Value D Growth B Momentum D VGM
Zacks News
MD vs. AVTR: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
MD vs. AVTR: Which Stock Is the Better Value Option?
Why Is Charles River (CRL) Down 5.3% Since Last Earnings Report?
by Zacks Equity Research
Charles River (CRL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is Pediatrix Medical Group (MD) Up 9.5% Since Last Earnings Report?
by Zacks Equity Research
Pediatrix Medical Group (MD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Avantor (AVTR) Inks Deal to Optimize Portfolio, Reduce Debt
by Zacks Equity Research
Avantor's (AVTR) latest agreement is likely to enhance its focus on strategic growth opportunities and reduce its debt burden.
Avantor's (AVTR) Q2 Earnings Beat, Operating Margin Declines
by Zacks Equity Research
Avantor's (AVTR) revenues decline in the second quarter with new segmental changes. Bioprocessing orders decline. Operating margin contracts.
Avantor, Inc. (AVTR) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Avantor (AVTR) delivered earnings and revenue surprises of 8.70% and 0.01%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Revvity (RVTY) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Revvity (RVTY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Avantor, Inc. (AVTR) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Avantor (AVTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Reasons Why You Should Hold Avantor (AVTR) Stock for Now
by Zacks Equity Research
Avantor's (AVTR) strong product portfolio raises optimism about the stock.
Avantor (AVTR) Launches Solutions for Gene Therapy Harvest
by Zacks Equity Research
Avantor's (AVTR) solutions are intended to provide gene therapy manufacturers with sustainable and efficient alternatives to traditional methods, thus improving viral particle harvest and quality
Reasons Why You Should Retain Avantor (AVTR) Stock for Now
by Zacks Equity Research
Avantor's (AVTR) strong product portfolio raises optimism about the stock.
Avantor (AVTR) Q1 Earnings Surpass Estimates, Margins Down
by Zacks Equity Research
Despite Avantor's (AVTR) continued stability in end markets, it reports an overall soft first-quarter performance.
The Zacks Analyst Blog Highlights Cigna Group, HCA Healthcare, Avantor and Tenet Healthcare
by Zacks Equity Research
Cigna Group, HCA Healthcare, Avantor and Tenet Healthcare are part of the Zacks top Analyst Blog.
Is a Surprise Coming for Avantor (AVTR) This Earnings Season?
by Zacks Equity Research
Avantor (AVTR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
ELV or AVTR: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ELV vs. AVTR: Which Stock Is the Better Value Option?
Stay Ahead With 4 Healthcare Stocks Poised for Q1 Earnings Beat
by Kaibalya Pravo Dey
Growing patient volumes, advancements in technology, admissions, premium rate hikes and other factors are likely to have benefited healthcare players during Q1. Companies like CI, HCA, AVTR and THC can outperform.
Analysts Estimate Bausch + Lomb (BLCO) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Bausch + Lomb (BLCO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Elevance (ELV) Q1 Earnings Beat on Rate Hikes, Guidance Raised
by Zacks Equity Research
Elevance Health (ELV) has a leftover capacity of around $3.6 billion under its share buyback authorization.
BLCO vs. AVTR: Which Stock Is the Better Value Option?
by Zacks Equity Research
BLCO vs. AVTR: Which Stock Is the Better Value Option?
Why Is Viatris (VTRS) Down 3.5% Since Last Earnings Report?
by Zacks Equity Research
Viatris (VTRS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Three Reasons to Retain Avantor (AVTR) Stock in Your Portfolio
by Zacks Equity Research
Avantor's (AVTR) strong product portfolio raises optimism about the stock.
BLCO or AVTR: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
BLCO vs. AVTR: Which Stock Is the Better Value Option?
Pediatrix Medical Group, Inc. (MD) Up 11% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Pediatrix Medical Group, Inc. (MD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
BLCO or AVTR: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
BLCO vs. AVTR: Which Stock Is the Better Value Option?
New Strong Sell Stocks for February 20th
by Zacks Equity Research
HAFC, AVTR and WHD have been added to the Zacks Rank #5 (Strong Sell) List on February 20, 2024.